Auauniversity

Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme CME Available: https://auau.auanet.org/content/aua-castration-resistant-prostate-cancer-crpc-guidelines-and-therapeutic-advances-metastatic Instructional Course Director(s) Michael Cookson, MD, MMHC Professor and Chair University of Oklahoma Instructional Course Faculty(s) David Jarrard, MD University of Wisconsin Adam Kibel, MD Brigham Health, Harvard University William Lowrance, MD University of Utah, Huntsman Cancer Institute This course will review the important and newly updated 2018 AUA Guidelines on Castration-Resistant Prostate Cancer. This includes a thorough discussion of new trials and approval of agents for MO non-metastatic nmCRPC. In addition, we will review therapeutic breakthroughs in the management of advanced and metastatic hormone naïve prostate cancer (mHSPPC). Faculty will highlight the management of